Voltron Therapeutics

Voltron Therapeutics, Inc. was founded in 2017 to lead and accelerate the development of novel self-assembling vaccine technology from the Vaccine and Immunotherapy Center (VIC) and Massachusetts General Hospital across various indications, including oncology and emerging infectious diseases. Voltron holds the global exclusive license for this technology. Through the efforts of our world-class team of researchers and physicians, this technology has demonstrated preliminary proof-of-concept in certain preclinical studies for two infectious diseases (Lassa fever and Q fever) as well as two oncology indications (ovarian and HPV-related).